.png){kind=icon}
返回
Complement contributions to COVID-19
.png){kind=icon}
PRE
AI
DOI：10.1097/MOH.0000000000000724.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Purpose of review COVID-19 remains a major source of concern, particularly as new variants emerge and with recognition that patients may suffer long-term effects. Mechanisms underlying SARS-CoV-2 mediated organ damage and the associated vascular endotheliopathy remain poorly understood, hindering new drug development. Here, we highlight selected key concepts of how the complement system, a major component of innate immunity that is dysregulated in COVID-19, participates in the thromboinflammatory response and drives the vascular endotheliopathy. Recent findings Recent studies have revealed mechanisms by which complement is activated directly by SARS-CoV-2, and how the system interfaces with other innate thromboinflammatory cellular and proteolytic pathways involving platelets, neutrophils, neutrophil extracellular traps and the coagulation and kallikrein-kinin systems. With this new information, multiple potential sites for therapeutic intervention are being uncovered and evaluated in the clinic. Infections with SARS-CoV-2 cause damage to the lung alveoli and microvascular endothelium via a process referred to as thromboinflammation. Although not alone in being dysregulated, complement is an early player, prominent in promoting the endotheliopathy and consequential organ damage, either directly and/or via the system's complex interplay with other cellular, molecular and biochemical pathways. Delineating these critical interactions is revealing novel and promising strategies for therapeutic intervention.
Keyword:
complement system
COVID-19
endothelium
innate immunity
kallikrein-kinin
neutrophil extracellular traps
neutrophils
platelets
SARS-CoV-2
期刊
IF:
2.9
论文数:
1.7K
被引数:
2.8K
机构
引用论文
Ineffective Degradation of Immunogenic Gluten Epitopes by Currently Available Digestive Enzyme Supplements.png)
PLOS ONE
OAAI
PLOS ONEIF0
OAAI分享收藏P1–133: Clusterin: An early biomarker for Alzheimer's disease?P1–133: Clusterin: 阿尔茨海默病的早期生物标志物？
PREAI
分享收藏
查看更多内容